Loading...
XKRX
145720
Market cap401mUSD
Jul 29, Last price  
64,700.00KRW
1D
-1.82%
1Q
-11.37%
IPO
82.25%
Name

Dentium Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
7.67
P/S
1.37
EPS
8,431.27
Div Yield, %
—
Shrs. gr., 5y
-0.13%
Rev. gr., 5y
10.05%
Revenues
407.81b
+3.72%
70,758,942,75061,976,635,65073,921,730,87087,142,224,11095,489,314,480120,033,552,220150,645,643,720186,316,233,650252,587,272,920229,749,431,320291,529,687,470355,865,975,040393,188,581,130407,807,117,930
Net income
72.71b
-24.67%
14,136,136,0007,410,915,89014,769,359,12016,140,928,86014,481,024,33019,793,092,31030,066,434,81034,253,295,53014,785,641,22022,544,714,00055,484,056,50086,066,136,12096,524,197,06772,710,126,070
CFO
36.46b
-43.89%
2,346,839,48014,380,771,07013,625,454,8206,162,926,17014,971,325,50017,601,158,70021,659,104,760-574,593,400-11,642,097,63075,754,918,14074,111,673,80047,011,431,13064,988,760,00036,464,161,770
Dividend
Dec 27, 2023400 KRW/sh
Earnings
Aug 12, 2025

Profile

Dentium Co.,Ltd. manufactures and sells dental implant products worldwide. Its dental implant systems include superline, implantium, simpleline II, slimline, overdenture system, NR line, and implantium II. The company also provides surgical instruments, such as surgical, drill stopper, sinus, osteotome, trephine bur, prosthetic, planning, restorative, and help kits, as well as harvest drills, sinus elevators, GBR systems, surgical guides, temporary shells, white seals, TN brushes, and guide systems; regeneration products, including bone grafts, membranes, and tissue regeneration products; and digital dentistry products. In addition, it offers lab products; and iCT motors and injections. The company was formerly known as Biostech Co., Ltd. and changed its name to Dentium Co.,Ltd. in August 2002. The company was founded in 2000 and is headquartered in Seoul, South Korea.
URL
https://www.dentium.co.kr/dsn/
IPO date
Mar 15, 2017
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
407,807,118
3.72%
393,188,581
10.49%
355,865,975
22.07%
Cost of revenue
231,554,471
185,791,058
157,777,021
Unusual Expense (Income)
NOPBT
176,252,647
207,397,523
198,088,954
NOPBT Margin
43.22%
52.75%
55.66%
Operating Taxes
21,522,379
37,954,241
32,250,961
Tax Rate
12.21%
18.30%
16.28%
NOPAT
154,730,268
169,443,282
165,837,993
Net income
72,710,126
-24.67%
96,524,197
12.15%
86,066,136
55.12%
Dividends
(3,449,556)
(2,587,167)
(2,155,973)
Dividend yield
0.64%
0.23%
0.25%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
211,535,923
163,633,126
138,269,316
Long-term debt
51,295,545
51,205,265
77,487,858
Deferred revenue
13,404
Other long-term liabilities
2,256,363
1,816,882
1,848,301
Net debt
153,930,744
127,926,605
107,025,355
Cash flow
Cash from operating activities
36,464,162
64,988,760
47,011,431
CAPEX
(18,283,083)
(44,146,509)
(54,111,178)
Cash from investing activities
(65,329,349)
(47,196,776)
(49,029,968)
Cash from financing activities
35,391,030
(2,791,589)
8,769,203
FCF
99,189,365
69,390,801
81,738,507
Balance
Cash
109,828,239
86,911,786
72,053,558
Long term investments
(927,515)
36,678,261
Excess cash
88,510,368
67,252,357
90,938,521
Stockholders' equity
502,106,814
432,477,583
343,849,065
Invested Capital
725,157,909
607,193,316
475,818,647
ROIC
23.23%
31.29%
38.48%
ROCE
21.69%
30.75%
34.95%
EV
Common stock shares outstanding
8,625
8,624
8,624
Price
62,200.00
-52.52%
131,000.00
31.00%
100,000.00
43.27%
Market cap
536,473,383
-52.51%
1,129,729,721
31.00%
862,389,100
43.27%
EV
689,243,602
1,256,926,872
968,697,268
EBITDA
199,458,855
228,281,687
217,037,499
EV/EBITDA
3.46
5.51
4.46
Interest
9,584,774
7,433,383
6,792,914
Interest/NOPBT
5.44%
3.58%
3.43%